Chemokine Study guides, Revision notes & Summaries

A patient developed type 4 PTLD three years after an allogeneic HSCT. Which of the following treatment interventions would the nurse expect an order for? - ANSWER-Aggressive chemotherapy Red bone marrow produces - ANSWER-hematopoietic stems cells that create red blood cells, white blood cells and platelets and is found in the long and flat bones yellow bone marrow and fat cells produce - ANSWER-stromal stem cells that produce fat, cartilage and bone and are found in the long bones. hemato...

BMTCN Test BTransplant-related toxicity is a barrier that contributes to the underutilization for which of the following diseases? A. Non-Hodgkin lymphoma B. Acute myeloid leukemia C. Sickle cell disease D. Neuroblastoma - correct answer C. Sickle cell disease Despite success of HSCT in sickle cell disease, barriers to successful HSCT include lack of a suitable donor, transplant related toxicity and immunologic graft rejection. Which of the following is a chemokine receptor that he...

Which of the following medications should a patient taking cyclosporine avoid following an allogenic HSCT? A. Torsemide B. Bumetanide C. Spironolactone D. Furosemide CORRECT ANSWER C. Patients taking cyclosporine should avoid potassium sparing diuretics such as spironolactone. How is bronchiolitis obliterans diagnosed? A. Pulmonary function test B. Broncho alveolar lavage C. Computed tomography scan D. Chest x-ray CORRECT ANSWER A. Pulmonary function test. Used to diagnose bronchiolit...

BMTCN A patient developed type 4 PTLD three years after an allogeneic HSCT. Which of the following treatment interventions would the nurse expect an order for? - correct answer Aggressive chemotherapy Red bone marrow produces - correct answer hematopoietic stems cells that create red blood cells, white blood cells and platelets and is found in the long and flat bones yellow bone marrow and fat cells produce - correct answer stromal stem cells that produce fat, cartilage and bone and are f...

Transplant-related toxicity is a barrier that contributes to the under utilization for which of the following diseases? A. Non-Hodgkin lymphoma B. Acute myeloid leukemia C. Sickle cell disease D. Neuroblastoma - ANSWER-C. Sickle cell disease Despite the success of HSCT in sickle cell disease, barriers to successful HSCT include lack of a suitable donor, transplant related toxicity and immunologic graft rejection. Which of the following is a chemokine receptor that helps to regulate stem...

BMTCN Practice Test A Questions with complete Answers Which of the following medications should a patient taking cyclosporine avoid following an allogenic HSCT? . How is bronchiolitis obliterans diagnosed? . Which of the following medications is a chemokine antagonist that is used for stem cell mobilization? Which of the following immunizations should an asplenic child who had a transplant receive? . Why is the additive DMSO used during stem cell processing? How many days shou...

BMTCN StudyMyeloid - correct answer erythrocyte, platelets, neutrophil, basophil, eosinophil, monoblastic, macrophage, monocyte lymphoid - correct answer pre- B cell, pre-t cell, plasma cell, natural killer cell, t lymphocyte innate immunity - correct answer occurs naturally- phagocytes release inflammatory mediators acquired immunity - correct answer response of either b or t cells to antigens senescence - correct answer loss of cells power to divide and grow immunosenescence - c...

BMTCN Test B Transplant-related toxicity is a barrier that contributes to the under utilization for which of the following diseases? A. Non-Hodgkin lymphoma B. Acute myeloid leukemia C. Sickle cell disease D. Neuroblastoma - ANSWER-C. Sickle cell disease Despite the success of HSCT in sickle cell disease, barriers to successful HSCT include lack of a suitable donor, transplant related toxicity and immunologic graft rejection. Which of the following is a chemokine receptor that helps to...

BMTCN Test B Questions & Answers 2023/2024 Transplant-related toxicity is a barrier that contributes to the under utilization for which of the following diseases? A. Non-Hodgkin lymphoma B. Acute myeloid leukemia C. Sickle cell disease D. Neuroblastoma - ANSWER-C. Sickle cell disease Despite success of HSCT in sickle cell disease, barriers to successful HSCT include lack of a suitable donor, transplant related toxicity and immunologic graft rejection. Which of the following is...

BMTCN Test B Transplant-related toxicity is a barrier that contributes to the underutilization for which of the following diseases? A. Non-Hodgkin lymphoma B. Acute myeloid leukemia C. Sickle cell disease D. Neuroblastoma - correct answer C. Sickle cell disease Despite success of HSCT in sickle cell disease, barriers to successful HSCT include lack of a suitable donor, transplant related toxicity and immunologic graft rejection. Which of the following is a chemokine receptor that ...